![]() Portola expects to launch Andexxa in early June to a limited number of hospitals (30 to 40) that are predominantly ANNEXA-4 clinical trial sites, along with a limited number of level 1 trauma centers and comprehensive stroke centers. Related: FDA reviewing safety of Parkinson’s drug “The price of Andexxa reflects its novel attributes, as well as its Orphan Drug Designation and the targeted population of high-risk patients that will benefit from the use of Andexxa,” a Portola spokesperson told FormularyWatch. ![]() ![]() The first-and-only antidote indicated for patients treated with rivaroxaban and apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding, will begin a limited rollout in June.Ĭoagulation factor Xa (recombinant), inactivated-zhzo (Andexxa, Portola Pharmaceuticals), which FDA approved in early May, costs $27,500 per gram, which approximates the average per patient dose. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |